Quote:

---

The question is, can the original off patent drug (bevacizumab) re-apply for patent in this combination treatment with leronlimab for this MSS mCRC indication and will that new patent again protect that newly patented drug Avastin + leronlimab for another 12 years?

---

Avastin would be the same as the original drug so no new patent or patent protection. Avastin would have to be substantially modified and gain a new patent. Avastin as an already approved drug would not get an FDA 12 year exclusivity either.